Current status of class III antiarrhythmic drug therapy
- 1 August 1993
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 72 (6), B44-B49
- https://doi.org/10.1016/0002-9149(93)90040-j
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Action potential prolongation and early afterdepolarizations induced by class III antiarrhythmic agents in the fetal but not in the adult rat heartJournal of Molecular and Cellular Cardiology, 1992
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Lack of Triggered Automaticity Despite Repolarization Abnormalities due to Bepridil and LidoflazinePacing and Clinical Electrophysiology, 1990
- Class III Antiarrhythrnic Action Linked with Positive Inotropy: Effects of the d‐ and 1‐Isomer of Sotalol on Isolated Rat Atria at Threshold and Suprathreshold StimulationBasic & Clinical Pharmacology & Toxicology, 1988
- Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient careAmerican Heart Journal, 1986
- Torsade de pointes: The long-short initiating sequence and other clinical features: observations in 32 patientsJournal of the American College of Cardiology, 1983
- Long-term antiarrhythmic therapy with acetylprocainamideThe American Journal of Cardiology, 1981
- Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamideThe American Journal of Cardiology, 1981
- Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: Comparison with procainamideThe American Journal of Cardiology, 1980
- Electrophysiologic comparative study of procainamide and N-acetylprocainamide in anesthetized dogs: concentration-response relationships.Circulation, 1979